

Figure S1. Prisma schematic.

The figure summarizes the phases of our literature search and their respective results.

Table S1. Incidence of any serious AE.

Study No.	First author	Any serious AE	Total number of patients	Treatment	Follow-up
1	Gordon [12]	0	52	Placebo	at week 12
1	Gordon [12]	1	45	Adalimumab	
2	Asahina [11]	2	46	Placebo	at week 24
2	Asahina [11]	3	43	Adalimumab	
3	Menter [13]	3	398	Placebo	at week 16
3	Menter [13]	10	814	Adalimumab	
4	Igarashi [16]	2	32	Placebo	at week 12
4	Igarashi [16]	0	64	Ustekinumab 45mg	
4	Igarashi [16]	3	62	Ustekinumab 90mg	
5	Papp 2008 [15]	8	410	Placebo	at week 12
5	Papp 2008 [15]	8	409	Ustekinumab 45mg	
5	Papp 2008 [15]	5	411	Ustekinumab 90mg	
6	Leonardi [18]	2	255	Placebo	at week 12
6	Leonardi [18]	2	255	Ustekinumab 45mg	
6	Leonardi [18]	4	255	Ustekinumab 90mg	
7	Tsai [17]	1	60	Placebo	at week 12
7	Tsai [17]	0	61	Ustekinumab 45mg	
8	Zhu [14]	1	161	Placebo	at week 12
8	Zhu [14]	1	160	Ustekinumab 45mg	
9	Tyring [22]	3	306	Placebo	at week 12
9	Tyring [22]	6	312	HDE	
10	Griffiths [23]	4	137	HDE	at week 12
10	Griffiths [23]	4	209	Ustekinumab 45mg	
10	Griffiths [23]	4	347	Ustekinumab 90mg	

Abbreviations: AE, adverse event; HDE, high-dose etanercept.

Table S2. Incidence of any infectious AE.

Study No.	First author	Any infectious AE	Total number of patients	Treatment	Follow-up
1	Menter [13]	89	398	Placebo	at week 16
1	Menter [13]	235	814	Adalimumab	
2	Asahina [11]	23	46	Placebo	at week 24
2	Asashina [11]	18	43	Adalimumab	
3	Papp [15]	82	410	Placebo	at week 12
3	Papp [15]	88	409	Ustekinumab 45mg	
3	Papp [15]	92	411	Ustekinumab 90mg	
4	Igarashi [16]	6	32	Placebo	at week 12
4	Igarashi [15]	13	64	Ustekinumab 45mg	
4	Igarashi [15]	15	62	Ustekinumab 90mg	
5	Leonardi [18]	68	255	Placebo	at week 12
5	Leonardi [18]	80	255	Ustekinumab 45mg	
5	Leonardi [18]	66	255	Ustekinumab 90mg	
6	Tsai [17]	14	60	Placebo	at week 12
6	Tsai [17]	20	61	Ustekinumab 45mg	
7	Zhu [14]	47	161	Placebo	at week 12
7	Zhu [14]	58	160	Ustekinumab 45mg	
8	Tyring [22]	71	306	Placebo	at week 12
8	Tyring [22]	87	312	HDE	
9	Papp [21]	25	193	Placebo	at week 12
9	Papp [21]	26	196	LDE	
9	Papp [21]	75	194	HDE	
10	Leonardi [20]	19	166	Placebo	at week 12
10	Leonardi [20]	16	160	LDE	
10	Leonardi [20]	9	164	HDE	
11	Van de Kerkhof [19]	12	46	Placebo	at week 24
11	Van de Kerkhof [19]	17	96	HDE	

Abbreviations: AE, adverse event; HDE, high-dose etanercept; LDE, low-dose etanercept.

Table S3. Any serious AE: results of Bayesian network meta-analysis for both direct and indirect comparisons.

Pairwise comparison		RD	95%CrI	
ADA	PLA	1.632	-0.371	6.007
U45	PLA	-0.159	-0.783	0.919
U90	PLA	-0.119	-0.784	1.017
HDE	PLA	1.357	-0.406	4.874
U45	ADA	-1.402	-2.590	1.286
U90	ADA	-1.348	-2.581	1.415
HDE	ADA	0.621	-2.294	7.620
U90	U45	0.120	-0.563	1.275
HDE	U45	1.744	-0.232	5.766
HDE	U90	1.682	-0.244	5.439

Abbreviations: CrI, credible interval; AE, adverse events; PLA, placebo; ADA, adalimumab; U45, ustekinumab 45 mg;

U90, ustekinumab 90 mg; HDE, high-dose etanercept.

Table S4. Results of the Bayesian network meta-analysis for both direct and indirect comparisons for the end-point of any infectious AE.

Pairwise comparison		RD	95%CrI	
ADA	PLA	5.368	0.359	10.729
U45	PLA	3.803	-0.162	7.844
U90	PLA	2.168	-2.042	6.597
HDE	PLA	8.172	2.859	13.670
LDE	PLA	-4.332	-9.752	1.842
U45	ADA	-1.229	-7.434	5.323
U90	ADA	-2.870	-9.091	3.947
HDE	ADA	3.174	-4.353	10.997
LDE	ADA	-9.435	-15.848	-1.840
U90	U45	-1.526	-5.678	2.871
HDE	U45	4.614	-2.250	11.788
LDE	U45	-7.962	-14.091	-0.934
HDE	U90	6.301	-0.888	13.818
LDE	U90	-6.289	-12.590	0.995
LDE	HDE	-12.393	-17.664	-6.398

Abbreviations: CrI, credible interval; AE, adverse event; PLA, placebo; ADA, adalimumab; U45, ustekinumab 45 mg; U90, ustekinumab 90 mg; HDE, high-dose etanercept; LDE low-dose etanercept.